Semaglutide Weight Management and Cardiovascular Risk Reduction
With CagriSema, time in range reached -90% at week 32 and
mean glucose levels decreased by ~64 mg/dL
Longer time in range for CagriSema vs semaglutide and cagrilintide
CagriSema
Semaglutide
Cagrilintide
1.5%
8.8%
8.7%
10.0%
17.8%
23.8%
15.0%
22.6%
32.5%
36.2%
45.9%
43.5%
88.9%
32.6%
5.5%
Time in range
Time in range goes "beyond" HbA1c for detailed
insights into glycemic control in people with
diabetes
Time in range (70-180 mg/dL) increased in all
groups, reaching 88.9% with CagriSema at week
32
76.2%
71.7%
56.9%
0.1%
0.8%
Baseline
Week 32
0.1%
Baseline
0.1%
Week 32
0.6%
Baseline
0.2%
Week 32
<70 mg/dL
70-180 mg/dL
>180-250 mg/dL
>250 mg/dL
Note: Data shown is trial product estimands
Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg
TIR: Time in range
•
Mean glucose levels
Decreased from baseline to week 32 in all
groups, reaching -63.9mg/dL for CagriSema,
-43.6 mg/dL for semaglutide and -23.4 mg/dL
for cagrilintideView entire presentation